Subjects who undergo Colon Capsule Endoscopy
Conditions
Interventions
A group Day before test: No administration of Polyethylene glycol(PEG). Test day: Administer PEG (2L). After completion of preparation, Colon Capsule procedure starts.
B group Day before test: Adm
Sponsors
National Cancer Center Hospital
Jikei University School of Medicine, Nagoya University, Osaka City University, Osaka Medical College, Hiroshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patients who have planned to undergo Colon Capsule procedure, or asymptomatic healthy volunteers - Obtaining informed consent
Exclusion criteria
Exclusion criteria: 1) Subjects who have a swallowing disorder 2) Subject who has 2 < bowel movements per week. 3) Subjects who take nonsteroidal anti-inflammatory drug for long period (more than 6 months) 4) Subjects who take anti-thrombotic medicine or anticoagulant 5) Subjects who take iron pills 6) Subjects who take morphine hydrochloride 7) Subjects who take tranquilizers 8) Subjects who have a history of allergic reaction to the following medicines (1 - 4) used in this study. These medicines are used normally in the clinical situations in Japan. 1. Magnesium citrate solution, Polyethylene glycol 2. Mosapride citrate 3. Dimethicone, Pronase, Sodium bicarbonate 4. Bisacodyl 5.Glycerin 6.sennoside 9) Subjects who are pregnant 10) Subjects who are scheduled to have MRI examination within the next 2 weeks 11) Subjects who have a cardiac pacemaker implanted or other medical electronic devices applied in the body 12) Subjects who have a history of digestive tract anastomosis 13) Subjects who have a history of abdominal operation 14) Subjects who have a suspected symptom or who have a history of intestinal obstruction or intestinal stenosis 15) Subjects who have a small intestine tumor or who have a suspected symptom of it 16) Subjects who have an advanced large intestine cancer or who have a suspected symptom of it 17) Subjects who have a diabetes 18) Subjects who have a diverticulum in digestive tract 19) Subjects who have a history of radiotherapy 20) Subjects who have an accompanying cancerous peritonitis 21) Subjects who have a renal dysfunction 22) Subjects who have a heart disease 23) Subjects who have a clone disease or ulcerative colitis 24) Subjects who have a familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC) 25) Subjects who had a incomplete total colonoscopy before 26) Other cases where doctor considers it inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Colon cleansing level and anus excretion rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Transit time in total digestive tract | — |
Countries
Japan
Contacts
Public ContactYasuo Kakugawa
National Cancer Center Hospital Endoscopy Division
Outcome results
None listed